title: Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: successful treatment with vincristine and ticlopidine.
authors.forename: Román
authors.initials: R
authors.lastname: Barabash-Neila
authors.forename: Esther
authors.initials: E
authors.lastname: García-Rodríguez
authors.forename: José
authors.initials: J
authors.lastname: Bernabeu-Wittel
authors.forename: Inmaculada
authors.initials: I
authors.lastname: Bueno-Rodríguez
authors.forename: Gemma
authors.initials: G
authors.lastname: Ramírez-Villar
authors.forename: Juan C
authors.initials: JC
authors.lastname: López-Gutierrez
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D005153:Facial Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006390:Hemangioendothelioma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007231:Infant, Newborn; D059885:Kasabach-Merritt Syndrome / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D058921:Purinergic P2Y Receptor Antagonists / Q000627:therapeutic use*; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000473:pathology; D013988:Ticlopidine / Q000627:therapeutic use*; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D058921:Purinergic P2Y Receptor Antagonists; D014750:Vincristine; D013988:Ticlopidine